262 related articles for article (PubMed ID: 34605330)
21. Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression.
Bandyopadhyay S; Zhan R; Chaudhuri A; Watabe M; Pai SK; Hirota S; Hosobe S; Tsukada T; Miura K; Takano Y; Saito K; Pauza ME; Hayashi S; Wang Y; Mohinta S; Mashimo T; Iiizumi M; Furuta E; Watabe K
Nat Med; 2006 Aug; 12(8):933-8. PubMed ID: 16862154
[TBL] [Abstract][Full Text] [Related]
22. Decreased expression of KAI1/CD82 metastasis suppressor gene is associated with loss of heterozygosity in melanoma cell lines.
Kim YI; Shin MK; Lee JW; Chung JH; Lee MH
Oncol Rep; 2009 Jan; 21(1):159-64. PubMed ID: 19082457
[TBL] [Abstract][Full Text] [Related]
23. Tetraspanin CD82 inhibits protrusion and retraction in cell movement by attenuating the plasma membrane-dependent actin organization.
Liu WM; Zhang F; Moshiach S; Zhou B; Huang C; Srinivasan K; Khurana S; Zheng Y; Lahti JM; Zhang XA
PLoS One; 2012; 7(12):e51797. PubMed ID: 23251627
[TBL] [Abstract][Full Text] [Related]
24. KAI1 inhibits HGF-induced invasion of pancreatic cancer by sphingosine kinase activity.
Liu X; Guo XZ; Zhang WW; Lu ZZ; Zhang QW; Duan HF; Wang LS
Hepatobiliary Pancreat Dis Int; 2011 Apr; 10(2):201-8. PubMed ID: 21459729
[TBL] [Abstract][Full Text] [Related]
25. Expression of KAI1/CD82 in distant metastases from estrogen receptor-negative breast cancer.
Christgen M; Christgen H; Heil C; Krech T; Länger F; Kreipe H; Lehmann U
Cancer Sci; 2009 Sep; 100(9):1767-71. PubMed ID: 19549254
[TBL] [Abstract][Full Text] [Related]
26. Expression of KITENIN, a KAI1/CD82 binding protein and metastasis enhancer, in bladder cancer cell lines: relationship to KAI1/CD82 levels and invasive behaviour.
Rowe A; Jackson P
Oncol Rep; 2006 Dec; 16(6):1267-72. PubMed ID: 17089048
[TBL] [Abstract][Full Text] [Related]
27. Role of tumor metastasis suppressor gene KAI1 in digestive tract carcinomas and cancer cells.
Wu Q; Ji Y; Zhang MQ; Chen YQ; Chen F; Shi DL; Zheng ZH; Huang YJ; Su WJ
Cell Tissue Res; 2003 Nov; 314(2):237-49. PubMed ID: 12955496
[TBL] [Abstract][Full Text] [Related]
28. Expression and clinical significance of p53, JunB and KAI1/CD82 in human hepatocellular carcinoma.
Guo C; Liu QG; Zhang L; Song T; Yang X
Hepatobiliary Pancreat Dis Int; 2009 Aug; 8(4):389-96. PubMed ID: 19666408
[TBL] [Abstract][Full Text] [Related]
29. Down Regulation of KAI1/CD82 in Lymph Node Positive and Advanced T-Stage Group in Breast Cancer Patients.
Krishna Latha T; Verma A; Thakur GK; Banerjee B; Kaur N; Singh UR; Sharma S
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3321-3329. PubMed ID: 31759355
[TBL] [Abstract][Full Text] [Related]
30. The metastasis suppressor CD82/KAI1 represses the TGF-β
Lee MS; Lee J; Kim YM; Lee H
Prostate; 2019 Sep; 79(12):1400-1411. PubMed ID: 31212375
[TBL] [Abstract][Full Text] [Related]
31. Serum metabolomics differentiating pancreatic cancer from new-onset diabetes.
He X; Zhong J; Wang S; Zhou Y; Wang L; Zhang Y; Yuan Y
Oncotarget; 2017 Apr; 8(17):29116-29124. PubMed ID: 28418859
[TBL] [Abstract][Full Text] [Related]
32. Normal viability of Kai1/Cd82 deficient mice.
Risinger JI; Custer M; Feigenbaum L; Simpson RM; Hoover SB; Webster JD; Chandramouli GV; Tessarollo L; Barrett JC
Mol Carcinog; 2014 Aug; 53(8):610-24. PubMed ID: 23401136
[TBL] [Abstract][Full Text] [Related]
33. The metastasis suppressor CD82/KAI1 inhibits fibronectin adhesion-induced epithelial-to-mesenchymal transition in prostate cancer cells by repressing the associated integrin signaling.
Lee J; Byun HJ; Lee MS; Jin YJ; Jeoung D; Kim YM; Lee H
Oncotarget; 2017 Jan; 8(1):1641-1654. PubMed ID: 27926483
[TBL] [Abstract][Full Text] [Related]
34. Identifying CD82 (KAI1) as a marker for human chromophobe renal cell carcinoma.
Yusenko MV; Kovacs G
Histopathology; 2009 Dec; 55(6):687-95. PubMed ID: 20002769
[TBL] [Abstract][Full Text] [Related]
35. Characteristics of the expression of KAI1/CD82 and PDGFRβ and their impact on glioma progression.
Paradowski M; Bilinska M; Bar J
Folia Neuropathol; 2016; 54(3):241-248. PubMed ID: 27764516
[TBL] [Abstract][Full Text] [Related]
36. KAI1 reverses the epithelial-mesenchymal transition in human pancreatic cancer cells.
Liu X; Guo XZ; Li HY; Chen J
Hepatobiliary Pancreat Dis Int; 2019 Oct; 18(5):471-477. PubMed ID: 30948327
[TBL] [Abstract][Full Text] [Related]
37. KAI1/CD82 expression as a prognosic factor in sporadic colorectal cancer.
Muneyuki T; Watanabe M; Yamanaka M; Shiraishi T; Isaji S
Anticancer Res; 2001; 21(5):3581-7. PubMed ID: 11848527
[TBL] [Abstract][Full Text] [Related]
38. KAI1/CD82, a tumor metastasis suppressor.
Liu WM; Zhang XA
Cancer Lett; 2006 Aug; 240(2):183-94. PubMed ID: 16260083
[TBL] [Abstract][Full Text] [Related]
39. Lower expression of KAI1 as a biomarker of poor survival prognosis of melanoma combined with colorectal cancer metastasis.
Du X; Wang B; Liu L; Li Y; Wang ZX; Zhang GJ; Yang XF
J Int Med Res; 2022 Aug; 50(8):3000605221116758. PubMed ID: 35942551
[TBL] [Abstract][Full Text] [Related]
40. KAI1 gene suppresses invasion and metastasis of hepatocellular carcinoma MHCC97-H cells in vitro and in animal models.
Yang JM; Peng ZH; Si SH; Liu WW; Luo YH; Ye ZY
Liver Int; 2008 Jan; 28(1):132-9. PubMed ID: 18028322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
